Cwm LLC Grows Position in Moderna, Inc. $MRNA

Cwm LLC raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 50.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 390,333 shares of the company’s stock after acquiring an additional 130,200 shares during the period. Cwm LLC’s holdings in Moderna were worth $10,082,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. World Investment Advisors purchased a new stake in shares of Moderna in the third quarter valued at about $318,000. Yousif Capital Management LLC increased its stake in Moderna by 5.0% in the 3rd quarter. Yousif Capital Management LLC now owns 47,090 shares of the company’s stock valued at $1,216,000 after buying an additional 2,234 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in Moderna by 21.3% in the 3rd quarter. Exchange Traded Concepts LLC now owns 42,914 shares of the company’s stock valued at $1,108,000 after buying an additional 7,545 shares during the last quarter. Douglas Lane & Associates LLC lifted its position in shares of Moderna by 21.3% during the 3rd quarter. Douglas Lane & Associates LLC now owns 1,128,434 shares of the company’s stock worth $29,147,000 after buying an additional 198,269 shares in the last quarter. Finally, Czech National Bank boosted its stake in shares of Moderna by 5.7% in the 3rd quarter. Czech National Bank now owns 87,948 shares of the company’s stock worth $2,272,000 after buying an additional 4,759 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director directly owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This trade represents a 85.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.90% of the company’s stock.

Moderna Stock Performance

MRNA stock opened at $31.20 on Monday. The stock has a fifty day moving average of $27.00 and a 200-day moving average of $27.39. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $48.92. The company has a market capitalization of $12.19 billion, a price-to-earnings ratio of -3.87 and a beta of 1.11.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($2.15) by $1.64. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The company’s revenue was down 45.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.03 earnings per share. Equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on MRNA. Jefferies Financial Group began coverage on Moderna in a research report on Friday, December 12th. They set a “hold” rating and a $30.00 price target for the company. Royal Bank Of Canada reduced their price objective on Moderna from $28.00 to $25.00 and set a “sector perform” rating for the company in a research note on Friday, November 21st. UBS Group reiterated a “buy” rating on shares of Moderna in a research note on Friday, November 21st. Leerink Partners increased their price target on shares of Moderna from $15.00 to $18.00 and gave the company an “underperform” rating in a research report on Friday, November 21st. Finally, Berenberg Bank set a $28.00 price objective on shares of Moderna in a report on Monday, November 17th. Two research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, Moderna has a consensus rating of “Reduce” and an average price target of $29.21.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.